

## Author Index to Volume 18 (1992)

- Agardh, C.-D., see Apelqvist, J. (18) 43  
Aizawa, T., see Okada, N. (18) 1  
Akinmokun, A., Harris, P., Home, P.D., Alberti, K.G.M.M.,  
Is diabetes always diabetes? (18) 131  
Alberti, K.G.M.M., see Akinmokun, A. (18) 131  
Ambrosi, F., see Gregorio, F. (18) 197  
Apelqvist, J., Agardh, C.-D., The association between clinical risk factors and outcome of diabetic foot ulcers (18) 43  
Arrol, S., see Winocour, P.H. (18) 173  
Aschner, P., Kattah, W., Effects of the combination of insulin and gliclazide compared with insulin alone in type 2 diabetic patients with secondary failure to oral hypoglycemic agent (18) 23  
  
Banchuin, C., see Thandhanand-Banchuin, N. (18) 17  
Beedham, T., see Toms, G.C. (18) 55  
Bhatnagar, D., see Winocour, P.H. (18) 173  
  
Carraro, P., see Finotti, P. (18) 35  
Caudwell, J., see Harrop, M. (18) 107  
Colman, P.G., see Harrop, M. (18) 107  
Cristallini, S., see Gregorio, F. (18) 197  
  
Day, S.L., see Toms, G.C. (18) 55  
Durrington, P.N., see Winocour, P.H. (18) 173  
  
Eguchi, H., see Tominaga, M. (18) 143  
Ekawa, K., see Ohagi, S. (18) 71  
Era, S., see Suzuki, E. (18) 153  
  
Fairbank, J., see Toms, G.C. (18) 55  
Filipponi, P., see Gregorio, F. (18) 197  
Finotti, P., Piccoli, A., Carraro, P., Alteration of plasma proteinase-antiproteinase system in type 1 diabetic patients. Influence of sex and relationship with metabolic control (18) 35  
Fisher, M., see Toms, G.C. (18) 55  
Fujii, S., see Miki, H. (18) 99  
  
Gregorio, F., Ambrosi, F., Cristallini, S., Pedetti, M., Filipponi, P., Santeusano, F., Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function (18) 197  
  
Halonen, J.-P., see Piha, S.J. (18) 61  
Han, M.C., see Kim, S.H. (18) 75  
Hanson, C., see Murthy, V.K. (18) 11  
Harris, P., see Akinmokun, A. (18) 131  
Harrop, M., Caudwell, J., Stojanovski, C., Colman, P.G., Insulin autoantibodies in patients with autoimmune diseases (18) 107  
Hitman, G.A., see McCarthy, M.I. (18) 31  
Home, P.D., see Akinmokun, A. (18) 131  
  
Igarashi, M., see Tominaga, M. (18) 143  
Ina, K., Kitamura, H., Nakamura, M., Ono, J., Takaki, R., Similarity of the constituents between glomerular arteriolar and mesangial lesions in experimental diabetes (18) 159  
Isaka, M., see Okuda, Y. (18) 139  
Ishola, M., see Winocour, P.H. (18) 173  
Ito, H., see Ohno, A. (18) 123  
Itoh, N., see Okada, N. (18) 1  
  
Kanazawa, A., see Ohno, A. (18) 123  
Katoh, K., Possible relevance of lipid peroxidation and thromboxane production to the initiation and/or evolution of microangiopathy in non-hyperlipidemic type 2 diabetes mellitus (18) 89  
Kattah, W., see Aschner, P. (18) 23  
Kespichayawatana, W., see Thandhanand-Banchuin, N. (18) 17  
Kim, S., see Kim, S.H. (18) 75  
Kim, S.M., see Kim, S.H. (18) 75  
Kim, S.H., Kim, S.M., Lee, H.K., Kim, S., Lee, J.S., Han, M.C., Diabetic nephropathy: duplex Doppler ultrasound findings (18) 75  
Kitamura, H., see Ina, K. (18) 159  
Kitaoka, H., see Sasaki, E. (18) 113  
Kobayashi, M., see Okada, N. (18) 1  
Komatsu, R., see Miki, H. (18) 99  
Komatsu, M., see Okada, N. (18) 1  
Kuwata, K., see Suzuki, E. (18) 153  
  
Lahti, J., see Niskanen, L. (18) 185  
Laohapand, T., see Thandhanand-Banchuin, N. (18) 17  
Latronico, M., see Papaccio, G. (18) 137  
Lee, J.S., see Kim, S.H. (18) 75  
Lee, H.K., see Kim, S.H. (18) 75

- Lekkerkerker, J.F.F., see Spooren, P.F.M.J. (18) 83  
 Lundquist, I., see Panagiotidis, G. (18) 167
- Mackness, M., see Winocour, P.H. (18) 173  
 Matsumoto, M., see Tominaga, M. (18) 143  
 Matsuyama, T., see Miki, H. (18) 99  
 Mbewu, A.D., see Winocour, P.H. (18) 173  
 McCarthy, M.I., Hitman, G.A., Mohan, V., Ramachandran, A., Snehalatha, C., Viswanathan, M., The islet amyloid polypeptide gene and non-insulin-dependent diabetes mellitus in South Indians (18) 31  
 Miki, H., Matsuyama, T., Fujii, S., Komatsu, R., Nishioeda, Y., Omae, T., Glucagon-glucose (GG) test for the estimation of the insulin reverse in diabetes (18) 99  
 Miura, K., see Suzuki, E. (18) 153  
 Miwa, T., see Ohno, A. (18) 123  
 Mizutani, M., see Okuda, Y. (18) 139  
 Mohan, V., see McCarthy, M.I. (18) 31  
 Monson, J.P., see Toms, G.C. (18) 55  
 Mori, M., see Shimizu, H. (18) 207  
 Moriya, T., see Okada, N. (18) 1  
 Murthy, V.K., Shipp, J.C., Hanson, C., Shipp, D., Delayed onset and decreased incidence of diabetes in BB rats fed free radical scavengers (18) 11
- Nakamura, M., see Ina, K. (18) 159  
 Nakazawa, K., see Okada, N. (18) 1  
 Nanjo, K., see Ohagi, S. (18) 71  
 Negishi, M., see Shimizu, H. (18) 207  
 Nishi, M., see Ohagi, S. (18) 71  
 Nishioeda, Y., see Miki, H. (18) 99  
 Niskanen, L., Lahti, J., Uusitupa, M., Morning or bed-time insulin with or without glibenclamide in elderly type 2 diabetic patients unresponsive to oral antidiabetic agents (18) 185
- Ohagi, S., Ekawa, K., Sanke, T., Nishi, M., Nanjo, K., Restriction fragment length polymorphisms near the islet amyloid polypeptide gene in Japanese subjects (18) 71  
 Ohno, A., Kanazawa, A., Tanaka, A., Miwa, T., Ito, H., Effect of a prostaglandin I<sub>2</sub> derivative (Iloprost) on peripheral neuropathy of diabetic rats (18) 123  
 Ohsawa, N., see Sasaki, E. (18) 113  
 Okada, N., Aizawa, T., Yokokawa, N., Kobayashi, M., Moriya, T., Shigematsu, S., Shiota, T., Komatsu, M., Shinoda, T., Yamada, T., Nakazawa, K., Itoh, N., Shigematsu, H., Abnormal molecular weight profile of urinary protein in rats with streptozotocin-induced diabetes (18) 1  
 Okamoto, N., see Sasaki, A. (18) 191  
 Okuda, Y., Mizutani, M., Tanaka, K., Isaka, M., Yamashita, K., Beneficial effects of eicosapentaenoic acid for diabetic patients with arteriosclerosis obliterans (18) 139  
 Omae, T., see Miki, H. (18) 99  
 Ono, J., see Ina, K. (18) 159
- Panagiotidis, G., Salehi, A.A., Westermark, P., Lundquist, I., Homologous islet amyloid polypeptide: effects on plasma levels of glucagon, insulin and glucose in the mouse (18) 167  
 Panpimarnmas, S., see Thandhanand-Banchuin, N. (18) 17  
 Papaccio, G., Latronico, M., Diabetes incidence and histopathological lesions in animal models (18) 137  
 Pattanapanyasat, K., see Thandhanand-Banchuin, N. (18) 17  
 Pedetti, M., see Gregorio, F. (18) 197  
 Piccoli, A., see Finotti, P. (18) 35  
 Piha, S.J., Halonen, J.-P., Effect of disease duration on cardiac autonomic reflexes in young patients with insulin-dependent diabetes mellitus (18) 61
- Ramachandran, A., see McCarthy, M.I. (18) 31
- Sakata, S., see Suzuki, E. (18) 153  
 Salehi, A.A., see Panagiotidis, G. (18) 167  
 Sanke, T., see Ohagi, S. (18) 71  
 Santeusano, F., see Gregorio, F. (18) 197  
 Sarasombath, S., see Thandhanand-Banchuin, N. (18) 17  
 Sasaki, H., see Tominaga, M. (18) 143  
 Sasaki, A., Okamoto, N., Epidemiology of childhood diabetes in Osaka District, Japan, using the documents from the medical benefits system specific for childhood diabetes (18) 159  
 Sasaki, E., Kitaoka, H., Ohsawa, N., Postprandial hypotension in patients with non-insulin-dependent diabetes mellitus (18) 113  
 Sekikawa, A., see Tominaga, M. (18) 143  
 Shigematsu, H., see Okada, N. (18) 1  
 Shigematsu, S., see Okada, N. (18) 1  
 Shimizu, H., Negishi, M., Shimomura, Y., Mori, M., Changes in urinary retinol binding protein excretion and other indices of renal tubular damage in patients with non-insulin dependent diabetes (18) 207  
 Shimomura, Y., see Shimizu, H. (18) 207  
 Shinoda, T., see Okada, N. (18) 1  
 Shipp, J.C., see Murthy, V.K. (18) 11  
 Shipp, D., see Murthy, V.K. (18) 11  
 Shiota, T., see Okada, N. (18) 1  
 Snehalatha, C., see McCarthy, M.I. (18) 31  
 Sogami, M., see Suzuki, E. (18) 153  
 Spooren, P.F.M.J., Lekkerkerker, J.F.F., Vermes, I., Micral-Test: a qualitative dipstick test for micro-albuminuria (18) 83  
 Stojanovski, C., see Harrop, M. (18) 107  
 Suzuki, E., Yasuda, K., Takeda, N., Sakata, S., Era, S., Kuwata, K., Sogami, M., Miura, K., Increased oxidized form of human serum albumin in patients with diabetes mellitus (18) 153
- Takaki, R., see Ina, K. (18) 159  
 Takeda, N., see Suzuki, E. (18) 153  
 Tanaka, A., see Ohno, A. (18) 123

- Tanaka, K., see Okuda, Y. (18) 139
- Thandhanand-Banchuin, N., Kespichayawatana, W., Vannasaeng, S., Banchuin, C., Laohapand, T., Panpimarnmas, S., Pattanapanyasat, K., Sarasombath, S., Webster, H.K., Presence of autoimmunity to pancreatic antigens in a patient with fibroacclulous pancreatic diabetes (18) 17
- Tominaga, M., Matsumoto, M., Igarashi, M., Eguchi, H., Sekikawa, A., Sasaki, H., Insulin antibody does not cause insulin resistance during glucose clamping in rats (18) 143
- Toms, G.C., Fairbank, J., Day, S.L., Fisher, M., Beedham, T., Monson, J.P., Outcome of gestational diabetes in Bengali Asians living in an East London health district (18) 55
- Uusitupa, M., see Niskanen, L. (18) 185
- Vannasaeng, S., see Thandhanand-Banchuin, N. (18) 17
- Vermes, I., see Spooren, P.F.M.J. (18) 83
- Viswanathan, M., see McCarthy, M.I. (18) 31
- Webster, H.K., see Thandhanand-Banchuin, N. (18) 17
- Westermarck, P., see Panagiotidis, G. (18) 167
- Winocour, P.H., Durrington, P.N., Bhatnagar, D., Mbewu, A.D., Ishola, M., Mackness, M., Arrol, S., A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with Type 1 (insulin-dependent diabetes mellitus (18) 173
- Yamada, T., see Okada, N. (18) 1
- Yamashita, K., see Okuda, Y. (18) 139
- Yasuda, K., see Suzuki, E. (18) 153
- Yokokawa, N., see Okada, N. (18) 1





## Key Word Index to Volume 18 (1992)

- $\beta_2$ -Adenoceptor stimulation; Mouse; Islet amyloid polypeptide; Plasma glucagon and insulin; Glucose (18) 167  
 A-kinase; Experimental diabetic neuropathy; Prostaglandin  $I_2$ ;  $Na^+$ ,  $K^+$ -ATPase; Cyclic AMP (18) 123  
 Abnormal glucose tolerance in Asians; Gestational diabetes (18) 55  
 Albuminuria; Diabetic nephropathy; Retinol binding protein;  $\beta_2$ -Microglobulin; *N*-Acetyl- $\beta$ -glucosaminidase (18) 207  
 Albuminuria; Fibrinogen; Type 1 diabetes; Coronary heart disease; Blood pressure; Lipids; Lipoprotein(a) (18) 173  
 Alloxan; Arteriolar hyalinosi; Mesangial expansion; PA-TCH-SP-PD; Type IV collagen; Fibronectin (18) 159  
 Amylin; Type 2 (non-insulin-dependent diabetes mellitus); Population study; South India; Islet amyloid polypeptide (18) 31  
 Arteriolar hyalinosi; Mesangial expansion; PA-TCH-SP-PD; Type IV collagen; Fibronectin; Alloxan (18) 159  
 Autoimmunity; Radiobinding assays; Insulin autoantibodies (18) 107  
 Autonomic nervous system; Autonomic neuropathy; Disease duration; Diabetes mellitus (18) 61  
 Autonomic neuropathy; Disease duration; Diabetes mellitus; Autonomic nervous system (18) 61  
 Autonomic neuropathy; Postprandial hypotension (PPH); Non-insulin-dependent diabetes mellitus; Twenty-four-hour ambulatory blood pressure monitoring (24-h ABPM); 75-g oral glucose tolerance test (75-g OGTT) (18) 113  
 BB rat; Hyperglycemia; Free radicals; Insulin-dependent diabetes (18) 11  
 Blood pressure; Lipids; Lipoprotein(a); Albuminuria; Fibrinogen; Type 1 diabetes; Coronary heart disease (18) 173  
 C-peptide; Glucagon-glucose test; Glucagon test; Residual B-cell function (18) 99  
 CD8<sup>+</sup> T lymphocytes; Islet cell antibodies (ICA); Lymphoproliferation assay; Pancreatic antigen; Fibrocalculus pancreatic diabetes (FCPD) (18) 17  
 Childhood diabetes; Incidence; Prevalence; Seasonal variation; Medical benefits system (18) 191  
 Clinical risk factors; Outcome; Diabetes mellitus; Foot ulcer (18) 43  
 Combined therapy; Non-insulin-dependent diabetes mellitus; Secondary failure; Gliclazide (18) 23  
 Coronary heart disease; Blood pressure; Lipids; Lipoprotein(a); Albuminuria; Fibrinogen; Type 1 diabetes (18) 173  
 Cyclic AMP; A-kinase; Experimental diabetic neuropathy; Prostaglandin  $I_2$ ;  $Na^+$ ,  $K^+$ -ATPase (18) 123  
 11-Dehydrothromboxane  $B_2$ ; Hyperlipidemia; Type 2 diabetes mellitus; Free radical; Lipid peroxides (18) 89  
 Diabetes mellitus; Autonomic nervous system; Autonomic neuropathy; Disease duration (18) 61  
 Diabetes mellitus; Foot ulcer; Clinical risk factors; Outcome (18) 43  
 Diabetes mellitus; Kidney, diseases; Kidney, parenchymal pattern; Kidney, US studies; Ultrasound, Doppler studies (18) 75  
 Diabetic nephropathy; Dipstick test; Micro-albuminuria (18) 83  
 Diabetic nephropathy; Retinol binding protein;  $\beta_2$ -Microglobulin; *N*-Acetyl- $\beta$ -glucosaminidase; Albuminuria (18) 207  
 Diabetic rats; Molecular weight profile; Urinary protein (18) 1  
 Diagnostic criteria; Non-insulin-dependent diabetes mellitus; Glucose tolerance; Obesity; Diet (18) 131  
 Diet; Diagnostic criteria; Non-insulin-dependent diabetes mellitus; Glucose tolerance; Obesity (18) 131  
 Dipstick test; Micro-albuminuria; Diabetic nephropathy (18) 83  
 Disease duration; Diabetes mellitus; Autonomic nervous system; Autonomic neuropathy (18) 61  
 Experimental diabetic neuropathy; Prostaglandin  $I_2$ ;  $Na^+$ ,  $K^+$ -ATPase; Cyclic AMP; A-kinase (18) 123  
 Fibrinogen; Type 1 diabetes; Coronary heart disease; Blood pressure; Lipids; Lipoprotein(a); Albuminuria (18) 173  
 Fibrocalculus pancreatic diabetes (FCPD); CD8<sup>+</sup> T lymphocytes; Islet cell antibodies (ICA); Lymphoproliferation assay; Pancreatic antigen (18) 17  
 Fibronectin; Alloxan; Arteriolar hyalinosi; Mesangial expansion; PA-TCH-SP-PD; Type IV collagen (18) 159  
 Foot ulcer; Clinical risk factors; Outcome; Diabetes mellitus (18) 43

Free radical; Lipid peroxides; 11-Dehydrothromboxane B<sub>2</sub>; Hyperlipidemia; Type 2 diabetes mellitus (18) 89  
Free radicals; Insulin-dependent diabetes; BB rat; Hyperglycemia (18) 11

Genetics; IAPP; NIDDM (18) 71

Gestational diabetes; Abnormal glucose tolerance in Asians (18) 55

Glibenclamide; Gliquidone; Gliclazide; Insulin; Glucagon; Isolated rat pancreas; Tolbutamide (18) 197

Glibenclamide; Insulin; Oral antidiabetic agent; Type 2 diabetic (18) 185

Gliclazide; Combined therapy; Non-insulin-dependent diabetes mellitus; Secondary failure (18) 23

Gliclazide; Insulin; Glucagon; Isolated rat pancreas; Tolbutamide; Glibenclamide; Gliquidone (18) 197

Gliquidone; Gliclazide; Insulin; Glucagon; Isolated rat pancreas; Tolbutamide; Glibenclamide (18) 197

Glucagon test; Residual B-cell function; C-peptide; Glucagon-glucose test (18) 99

Glucagon; Isolated rat pancreas; Tolbutamide; Glibenclamide; Gliquidone; Gliclazide; Insulin (18) 197

Glucagon-glucose test; Glucagon test; Residual B-cell function; C-peptide (18) 99

Glucose clamp; Insulin antibody; Insulin resistance (18) 143

Glucose tolerance; Obesity; Diet; Diagnostic criteria; Non-insulin-dependent diabetes mellitus (18) 131

Glucose;  $\beta_2$ -Adenoceptor stimulation; Mouse; Islet amyloid polypeptide; Plasma glucagon and insulin (18) 167

Human serum albumin; Mercapt and nonmercapt conversion (18) 153

Hyperglycemia; Free radicals; Insulin-dependent diabetes; BB rat (18) 11

Hyperlipidemia; Type 2 diabetes mellitus; Free radical; Lipid peroxides; 11-Dehydrothromboxane B<sub>2</sub> (18) 89

IAPP; NIDDM; Genetics (18) 71

Incidence; Prevalence; Seasonal variation; Medical benefits system; Childhood diabetes (18) 191

Insulin antibody; Insulin resistance; Glucose clamp (18) 143

Insulin autoantibodies; Autoimmunity; Radiobinding assays (18) 107

Insulin resistance; Glucose clamp; Insulin antibody (18) 143

Insulin; Glucagon; Isolated rat pancreas; Tolbutamide; Glibenclamide; Gliquidone; Gliclazide (18) 197

Insulin; Oral antidiabetic agent; Type 2 diabetic; Glibenclamide (18) 185

Insulin-dependent diabetes; BB rat; Hyperglycemia; Free radicals (18) 11

Islet amyloid polypeptide; Amylin; Type 2 (non-insulin-dependent diabetes mellitus); Population study; South India (18) 31

Islet amyloid polypeptide; Plasma glucagon and insulin; Glucose  $\beta_2$ -Adenoceptor stimulation; Mouse (18) 167

Islet cell antibodies (ICA; Lymphoproliferation assay; Pancreatic antigen; Fibrocalculus pancreatic diabetes (FCPD); CD8<sup>+</sup> T lymphocytes (18) 17

Isolated rat pancreas; Tolbutamide; Glibenclamide; Gliquidone; Gliclazide; Insulin; Glucagon (18) 197

Kidney, diseases; Kidney, parenchymal pattern; Kidney, US studies; Ultrasound, Doppler studies; Diabetes mellitus (18) 75

Kidney, parenchymal pattern; Kidney, US studies; Ultrasound, Doppler studies; Diabetes mellitus; Kidney, diseases (18) 75

Kidney, US studies; Ultrasound, Doppler studies; Diabetes mellitus; Kidney, diseases; Kidney, parenchymal pattern (18) 75

Lipid peroxides; 11-Dehydrothromboxane B<sub>2</sub>; Hyperlipidemia; Type 2 diabetes mellitus; Free radical (18) 89

Lipids; Lipoprotein(a); Albuminuria; Fibrinogen; Type 1 diabetes; Coronary heart disease; Blood pressure (18) 173

Lipoprotein(a); Albuminuria; Fibrinogen; Type 1 diabetes; Coronary heart disease; Blood pressure; Lipids (18) 173

Lymphoproliferation assay; Pancreatic antigen; Fibrocalculus pancreatic diabetes (FCPD); CD8<sup>+</sup> T lymphocytes; Islet cell antibodies (ICA) (18) 17

Medical benefits system; Childhood diabetes; Incidence; Prevalence; Seasonal variation (18) 191

Mercapt and nonmercapt conversion; Human serum albumin (18) 153

Mesangial expansion; PA-TCH-SP-PD; Type IV collagen; Fibronectin; Alloxan; Arteriolar hyalinosis (18) 159

Metabolic control; Proteinases; Proteinase inhibitors; Sex (18) 35

Micro-albuminuria; Diabetic nephropathy; Dipstick test (18) 83

Molecular weight profile; Urinary protein; Diabetic rats (18) 1

$\beta_2$ -Microglobulin; N-Acetyl- $\beta$ -glucosaminidase; Albuminuria; Diabetic nephropathy; Retinol binding protein (18) 207

Mouse; Islet amyloid polypeptide; Plasma glucagon and insulin; Glucose;  $\beta_2$ -Adenoceptor stimulation (18) 167

N-Acetyl- $\beta$ -glucosaminidase; Albuminuria; Diabetic nephropathy; Retinol binding protein;  $\beta_2$ -Microglobulin (18) 207

Na<sup>+</sup>, K<sup>+</sup>-ATPase; Cyclic AMP; A-kinase; Experimental diabetic neuropathy; Prostaglandin I<sub>2</sub> (18) 123

NIDDM; Genetics; IAPP (18) 71

Non-insulin-dependent diabetes mellitus; Glucose tolerance; Obesity; Diet; Diagnostic criteria (18) 131

Non-insulin-dependent diabetes mellitus; Secondary failure; Gliclazide; Combined therapy (18) 23

Non-insulin-dependent diabetes mellitus; Twenty-four-hour ambulatory blood pressure monitoring (24-h ABPM); 75-g oral glucose tolerance test (75-g OGTT); Autonomic neuropathy; Postprandial hypotension (PPH) (18) 113

Obesity; Diet; Diagnostic criteria; Non-insulin-dependent diabetes mellitus; Glucose tolerance (18) 131

Oral antidiabetic agent; Type 2 diabetic; Glibenclamide; Insulin (18) 185

75-g oral glucose tolerance test (75-g OGTT); Autonomic neuropathy; Postprandial hypotension (PPH); Non-insulin-dependent diabetes mellitus; Twenty-four-hour ambulatory blood pressure monitoring (24-h ABPM) (18) 113

Outcome; Diabetes mellitus; Foot ulcer; Clinical risk factors (18) 43

PA-TCH-SP-PD; Type IV collagen; Fibronectin; Alloxan; Arteriolar hyalinosis; Mesangial expansion (18) 159

Pancreatic antigen; Fibrocalculus pancreatic diabetes (FCPD); CD8<sup>+</sup> T lymphocytes; Islet cell antibodies (ICA; Lymphoproliferation assay (18) 17

Plasma glucagon and insulin; Glucose;  $\beta_2$ -Adenoceptor stimulation; Mouse; Islet amyloid polypeptide (18) 167

Population study; South India; Islet amyloid polypeptide; Amylin; Type 2 (non-insulin-dependent diabetes mellitus) (18) 31

Postprandial hypotension (PPH); Non-insulin-dependent diabetes mellitus; Twenty-four-hour ambulatory blood pressure monitoring (24-h ABPM); 75-g oral glucose tolerance test (75-g OGTT); Autonomic neuropathy (18) 113

Prevalence; Seasonal variation; Medical benefits system; Childhood diabetes; Incidence (18) 191

Prostaglandin I<sub>2</sub>; Na<sup>+</sup>, K<sup>+</sup> ATPase; Cyclic AMP; A-kinase; Experimental diabetic neuropathy (18) 123

Proteinase inhibitors; Sex; Metabolic control; Proteinases (18) 35

Proteinases; Proteinase inhibitors; Sex; Metabolic control (18) 35

Radiobinding assays; Insulin autoantibodies; Autoimmunity (18) 107

Residual B-cell function; C-peptide; Glucagon-glucose test; Glucagon test (18) 99

Retinol binding protein;  $\beta_2$ -Microglobulin; N-Acetyl- $\beta$ -glucosaminidase; Albuminuria; Diabetic nephropathy (18) 207

Seasonal variation; Medical benefits system; Childhood diabetes; Incidence; Prevalence (18) 191

Secondary failure; Gliclazide; Combined therapy; Non-insulin-dependent diabetes mellitus (18) 23

Sex; Metabolic control; Proteinases; Proteinase inhibitors (18) 35

South India; Islet amyloid polypeptide; Amylin; Type 2 (non-insulin-dependent diabetes mellitus); Population study (18) 31

Tolbutamide; Glibenclamide; Gliquidone; Gliclazide; Insulin; Glucagon; Isolated rat pancreas (18) 197

Twenty-four-hour ambulatory blood pressure monitoring (24-h ABPM); 75-g oral glucose tolerance test (75-g OGTT); Autonomic neuropathy; Postprandial hypotension (PPH); Non-insulin-dependent diabetes mellitus (18) 113

Type 1 diabetes; Coronary heart disease; Blood pressure; Lipids; Lipoprotein(a); Albuminuria; fibrinogen (18) 173

Type 2 (non-insulin-dependent diabetes mellitus); Population study; South India; Islet amyloid polypeptide; Amylin (18) 31

Type 2 diabetes mellitus; Free radical; Lipid peroxides; 11-Dehydrothromboxane B<sub>2</sub>; Hyperlipidemia (18) 89

Type 2 diabetic; Glibenclamide; Insulin; Oral antidiabetic agent (18) 185

Type IV collagen; Fibronectin; Alloxan; Arteriolar hyalinosis; Mesangial expansion; PA-TCH-SP-PD (18) 159

Ultrasound, Doppler studies; Diabetes mellitus; Kidney, diseases; Kidney, parenchymal pattern; Kidney, US studies (18) 75

Urinary protein; Diabetic rats; Molecular weight profile (18)